Glance Editorial Team

Switzerland-based Haag-Streit AG has released a new corneal ectasia display for its Eyestar 900 swept-source-based precision optical coherence tomography (OCT) analyzer.

 is designed to provide highly accurate laser optic measurements of the eye, from the cornea to the retina.

As the first optical biometer on the market that measures the thickness of the crystalline lens, it includes a user-friendly interface and optimized workflow to provide precise measurements. Data from high-quality cross-sectional eye images can be acquired in an estimated 40 seconds.

 features swept-source OCT (SS-OCT) biometry, dual-zone precision keratometry, anterior and posterior corneal topography, lens tilt analysis, vision simulation, and Zernike wavefront (as well as built-in IOL calculation methods such as 

Using SS-OCT-based biometry, the device’s 

covers up to 12 mm diameter on the anterior and posterior cornea, as well as 18 mm diameter OCT images of the anterior chamber (for analysis of lens structure, chamber angle, or implantable collamer lens [ICL] vault.)

 technology includes trajectories of the scan aligned in an interwoven and dense pattern that combine with OCT-inherent motion compensation to deliver a highly-precise, three-dimensional data set.

The new corneal ectasia display features the following:

OCT-based topography to record elevation information from the front and back surface of the cornea

Belin ABCD grading, which defines keratoconus up to four parameters

Complementary parameters for identifying early signs of ectatic changes and keratoconus.

Unfortunately, the unit is not currently available in the US at this time. Contact Haag Streit to learn more 

Fully-automated device is the first optical biometer on the market that measures crystalline lens thickness.

Haag-Streit launches new corneal ectasia display for Eyestar 900

 found that the majority of patients who qualify for low vision services never actually receive treatment—due in large part to eye care practitioners’ (ECPs’) and patients’ perceptions.

Investigators from the University of Wisconsin gathered electronic medical records (EMRs) of 2,014 patients with visual acuity (VA) of 20/70 or worse between 2014 and 2019.

Patients were separated into two groups based on the VA in their better-seeing eye: Group 1 with a VA of 20/70 to 20/200 (91.7% of patients) and Group 2 with a VA of 20/200 to worse vision.

Note: a low vision program was established in 2017 that was significantly advertised to the participating patients.

The records were reviewed to determine which patients qualifying for low vision services actually went on to receive care—and, thus, identify gaps in the referral process.

Investigators found that 89.8% of patients with a VA of 20/70 to 20/200 (Group 1) and 74.4% of patients with VA worse than 20/200 (Group 2) did not receive any referrals for low vision.

Prior to the establishment of the low vision program, only 2.2% of patients in Group 1 received a referral on their first visit; that percentage jumped to 8% after the program opened (odds ratio [OR], 3.88; 95% confidence interval [CI], 2.37 to 6.33; P < .001).

In Group 2, 12% of patients were referred for low vision services on their first visit prior to the program being established; post-establishment, 31.9% received referrals (OR, 3.29; 95% CI, 1.50 to 7.19; P = .002).

Overall patients in Group 2 (with VA 20/200 or worse) were more likely to be referred than in Group 1.

The study authors noted that 10.3% of patients declined to receive low vision services.

The authors stated that perception toward low vision rehabilitative services may have played a key role in referral outcomes, and that ECPs play an important role in how that perception is driven.

Researchers concluded that, while the low vision program establishment increased the number of low vision care referrals for study patients, improvement is necessary.

“We hope to break down patients’ misconceptions of low vision services and deconstruct providers’ assumption that low vision services are a last-resort treatment for those with poor vision,” they stated. “Ultimately, we want to break societal stigmas and promote a positive perception of low vision services in the community to increase access and timely referrals.”

Research finds that the majority of qualifying patients do not receive care. 

Referral rates impact perception of low vision services

, Bausch + Lomb Corporation and Novaliq GmbH have 

 from their second pivotal MOJAVE phase 3 trial on 

 (perfluorohexyloctane) for dry eye disease (DED) associated with meibomian gland dysfunction (MGD).

NOV03 is an investigational proprietary, non-steroidal, water-free, and preservative-free ophthalmic drop based on Novaliq’s patented 

The drop spreads rapidly across the ocular surface due to its low surface tension, and interacts with the lipophilic part of the tear film that prevents tear evaporation.

It also can penetrate the meibomian glands, where it interacts with and dissolves altered, viscous meibum in the glands.

Give me some background on its development.

Novaliq entered into a strategic cooperation agreement with Bausch + Lomb in 2019 to develop, manufacture, and commercialize NOV03 in the U.S. and Canada.

The FDA accepted its new drug application (NDA) filing in September 2022.

 showed that NOV03 demonstrated statistically significant and clinically meaningful improvements for patients with DED associated with MGD in comparison to a placebo (hypotonic saline). Additionally, DED signs and symptoms were well tolerated.

Now talk about this second phase 3 trial.

The second pivotal MOJAVE trial was a multi-center, randomized, hypotonic saline-controlled, double-masked study. A total of 620 patients (ages 18+) with DED were randomized to receive either NOV03 four times a day (n = 311) or the hypotonic solution four times a day (n=309) for eight weeks.

Primary endpoints included change from baseline at Week 8 in total corneal fluorescein staining (tCFS) and eye dryness Visual Analog Scale (VAS) Score.

Secondary endpoints included change from baseline in eye dryness VAS Score and tCFS at Week 2 and eye burning/stinging VAS score and central corneal fluorescein staining (cCFS) at Week 8.

At Week 8, for the primary endpoints, reduction from baseline in tCFS was statistically greater in the NV03 group compared to control (-1.2 vs -0.8, P < .001); and the VAS dryness score was statistically significantly improved for the NOV03 arm compared to control (-14.4 vs -6.1, P < .001).

At Week 2, for secondary endpoints, tCSF and VAS dryness score were both statistically significant compared to saline: –1.0 vs -0.2 (P = .001) for tCSF; -11.3 vs -4.3 (P < .001).

And at Week 8, VAS burning/stinging score and cCFs were greater in the NOV03 group: -11,3 vs -3.4 (P < .001) and -0.5 vs -0.2 (P < .001), respectively.

Ocular adverse events (AEs) were found in 12.9% of the NOV03 group and 12.3% in the control group, while treatment-related ocular AEs occurred in 6.4% (NOV03 group) and 6.8% (control group).

The most common AEs among the NOV03 group included blepharitis, conjunctival hyperemia and papillae, ocular hyperemia, blurred vision, and VA reduction.

With no current FDA-approved therapies that directly target evaporation in DED associated with MGD, the data holds promise for NOV03 to be the first, pending approval.

A target Prescription Drug User Fee Act (PDUFA) action date has been set for June 28, 2023.

Results from MOJAVE study support potential for treating DED associated with MGD.

Bausch + Lomb

Novaliq

Bausch + Lomb, Novaliq release second phase 3 data for NOV03

 evaluated the rates of incidence and progression of diabetic retinopathy (DR) in American Indian and Alaska Native patients.

While rates of DR have declined, the prevalence of diabetes in American Indian and Alaska Native people is currently 14.7%, which is higher than other racial and ethnic groups in the US.

Prior to this study, estimates of DR incidence and progression in American Indian and Alaska Native people were based on data from before 1992, potentially making the data inaccurate.

This retrospective cohort study used de-identified medical record data obtained during routine clinical operations from the 

 teleophthalmology program at 75 primary care clinics across 20 U.S. states. The IHS serves enrolled members of federally recognized tribes.

Investigators reviewed the data from 8,374 American Indian and Alaska Native patients seen between 2015 and 2019. Within the cohort, in 2015, the mean age was 53.2 years (standard deviation [SD] 12.2 years), 57% of participants were female, and the mean hemoglobin A1c level was 8.3% (SD 2.2%).

To be included in the study, eligible patients had to be 20 years or older, have no evidence of DR, or have mild nonproliferative DR (NPDR) during the baseline period.

Patients with severe NPDR or any level of diabetic macular edema (DME) were excluded from the study.

The study found that of the patients with no DR in 2015, 18% (1,280 of 7,097) had mild NPDR or worse from 2016 to 2019, and 0.1% (10 of 7,097) had proliferative DR (PDR). The incident rate from no DR to any DR was 69.6 cases per 1,000 person-years at risk.

A total of 6.2% (441 of 7,097) participants progressed from no DR to moderate NPDR or worse, meaning a 2+ step increase, with an incident rate of 24 cases per 1,000 person-years at risk.

Of patients with mild NPDR in 2015, 27.2% (347 of 1,277) progressed to moderate NPDR or worse from 2016 to 2019, and 2.3% (30 of 1,277) progressed to severe NPDR or worse (i.e., 2+ step progression).

An association was observed between the incidence and progression of DR and the expected risk factors and evaluation with ultra-widefield imaging.

Compared to the data recorded in 1992, according to the study authors, these results point to the “viability of safely extending the follow-up interval for retinopathy assessment in IHS patients who have no evidence of DR or mild NPDR.”

Study shows lower DR incidence rate and progression compared to 30 years ago.

New data on DR progression in Native Americans

 it has concluded enrollment and conducted the last visit in its pivotal phase 3 trial BRIO-1 for its lead investigational asset, BRIMOCHOL PF—a once-daily eye drop—to correct the loss of near vision associated with presbyopia.

BRIMOCHOL PF is a topical, preservative-free, and fixed-dose ophthalmic solution consisting of a combination of carbachol and brimonidine tartrate (both FDA-approved).

The formulation creates and sustains a “pinhole effect” by reducing the pupil size to allow only centrally-focused light rays to enter the eye, resulting in enhanced, sustainable vision and clarity for near (i.e. reading, smartphone/tablet use) and intermediate visual tasks (i.e. staring at a computer screen).

is a cholinergic agent that is known for its potency and increased duration of activity as a miotic agent—meaning it reduces the size of the pupil, leading to near visual acuity (VA) improvement—via pupil constriction.

 is a highly selective alpha-2 agonist that prevents ciliary muscle contraction by way of alpha-2 receptor activation. Thus, this sympatholytic agent can potentially mitigate miotic side effects.

According to Visus, the double-masked, randomized, multi-center, safety and efficacy study (

) is enrolling 450 patients (ages 45-80) diagnosed with emmetropic phakic and pseudophakic presbyopia.

Participants will receive either a combined single drop of BRIMOCHOL PF, a single drop of Carbachol PF, or a single drop of vehicle at each visit.

The primary outcome measurement is the percentage of patients with 3-line improvement in near VA without the loss of 1 line in distance VA.

Visus expects to have a data readout by Q2 2023 (the study’s Clinical Trials page estimates 

According to Rhett Schiffman, MD, MS, MHSA, Visus co-founder, chief medical officer and head of research and development, the company has the potential to “become the first company to meet this FDA-required high bar for approving a combination product for presbyopia in a pivotal phase 3 study.”

Pivotal study is assessing safety and efficacy of the combined, fixed-dosage of carbachol and brimonidine tartrate.

Visus Therapeutics

Visus completes enrollment for phase 3 trial of Brimochol PF for presbyopia

The Federal Trade Commission (FTC) will hold a 

 to assess changes that have been proposed to the Ophthalmic Practice Rules (better known as the Eyeglass Rule).

Give me some background on this rule first.

in 1978 to require eye care practitioners (ECPs) to give patients a copy of their prescription after an eye exam for no extra cost.

The rule also prohibits eye care practitioners (ECPs) from requiring patients to purchase ophthalmic goods—including contact lenses and eyeglasses—from their office as a requirement for receiving an eye exam that includes a refraction (even if a patient does not request it).

Additionally, ECPs are prohibited from requiring patients to pay additional fees, sign a waiver, or a release as a condition of verifying or releasing a prescription.

 a proposal in December 2022 to update the Eyeglass Rule to include the following:

Pending a patient’s consent, ECPs can provide a digital copy of the glasses and/or contact lens prescription in lieu of a paper copy.

Verify that a patient's proof of insurance will be payment choice for when a prescription must be provided.

Amend the term “eye examination” to “refractive eye examination” throughout the rule.

According to the FTC, consumer complaints regarding violations to this rule over the past few years have led to warning letters being issued.

 to ECPs across the country for failing to comply with the rules in January 2023 while 

The proposed changes, as conveyed by the FTC, are a means to ensure consumers' choices are protected from prescribers who fail to give patients their prescriptions automatically.

,” the free workshop will be held as a half-day event, open to the public, on May 19, 2023, in Washington, DC, at the Constitution Center from 9 am to 1 pm ET in the first-floor conference room. A livestream will also be available.

The event is being held in conjunction with the FTC’s regulatory review of the Eyeglass Rule (

). A more detailed agenda is expected to be released in the coming weeks.

 to participate as a panel for the workshop now through April 7, 2023.



 are welcome until June 20, 2023, for those interested in providing input on the event’s discussion topics.

Free, half-day event will focus on consumer and prescriber protections.

FTC to host public workshop on proposed Eyeglass Rule changes

The Centers for Disease Control and Prevention (CDC) 

 that, as of March 14, 2023, two more deaths have been reported and the number of infection cases and states have risen due to the outbreak of an extensively drug-resistant bacteria associated with the previously recalled EzriCare Artificial Tears.

 that it was investigating an outbreak of cases of Verona Integron‐mediated Metallo‐β‐lactamase (VIM)‐ and Guiana‐Extended Spectrum‐β‐Lactamase (GES)‐ producing carbapenem‐resistant Pseudomonas aeruginosa (VIM‐GES‐CRPA) in clusters within multiple states that were linked to various infection sites (inclusive of ocular tissues).

The outbreak is connected to the use of 10 different brands of over-the-counter (OTC) artificial tears, with EzriCare Artificial Tears being the most commonly-reported brand used by consumers. 

The CDC originally issued a voluntary recall for EzriCare, which was then escalated to Health Alert Network (HAN) Advisory in 

  that mandated all eye care practitioners (ECPs) and patients immediately stop use of the eye drops.

Also of note, a recall was issued for Delsam Pharma’s artificial tears.

The CDC confirmed that two more patient deaths were reported among those infected by the VIM-GES-CRPA bacteria (for a total of three deaths).

Further, out of the 68 patient cases across 

, there have been eight reports of vision loss and four reports of enucleation (surgical removal of an eyeball).

What other symptoms have patients reported?

The CDC indicated that additional eye infection symptoms may include:

Yellow, green, or clear discharge from the eye

The CDC also announced that researchers from University of California, San Diego have identified a bacteriophage that may potentially treat the bacteria, which is known to be extensively drug-resistant.

Previous research from the university’s Center for Innovative Phage Applications and Therapeutics includes the development of 

 to treat patients with infections caused by drug-resistant bacteria.

According to the CDC, no infected patients have been treated with this therapy as of the time of this report.

The CDC stated that any clinicians and patients should immediately stop using EzriCare Artificial Tears pending additional guidance from the CDC and FDA.

CDC reports two more patients have died due to infection from EzriCare Artificial Tears, among other products.

EzriCare

Death toll rises in artificial tears recall

 for the first and only U.S. non-profit organization focused on the disease. 

Currently, about 4 million Americans live with Sjögren’s, which is a systemic autoimmune disease that affects the entire body. The autoimmune response in Sjögren’s occurs from mononuclear infiltration of the salivary and lacrimal glands, leading to complaints of dry mouth and dry eyes.

A main symptom  is dry eye disease (DED)as Sjögren’s attacks exocrine glands of mucous membranes. Sometimes, a DED diagnosis will precede other systemic symptoms of Sjögren’s by years.

As a result, optometrists may be some of the first healthcare providers to identify the possibility of the condition.

 is the first and only non-profit health organization in the United States that is focused on the improving support, diagnosis, and education of the disease.

With 65 active support groups across the country—and partnerships with various foreign countries— the organization raises over $2.5 million annually in support of its mission and invests $400,000 in Sjögren’s research initiatives and patient services.

—across the globe—February 24-25, 2023

Eight sessions were featured in the clinical track and 10 sessions in the implementation track.

In the words of the Sjögren's Foundation CEO and President Janet Church, “We appreciate the generosity of the eyecare community to build awareness of Sjögren's,” she said. “We are in lockstep with optometrists and ophthalmologists when it comes to providing relief from dry eye symptoms—and there’s no better event to share knowledge about [DED] than Eyes On Dry Eye.”

This year’s event raised $1,100 for the first and only U.S. non-profit organization focused on the disease. 

Eyes On Eyecare

Eyes On Dry Eye raises over $1K for Sjögren’s Foundation

New research out of the National Eye Institute (NEI) supports the development of artificial intelligence/machine learning (AI/ML)-based systems that are focused on preventive measures for patients with age-related macular degeneration (AMD).

These AI/ML-based systems are designed to not only screen for AMD, but also predict which patients may be likely to progress to late AMD within 2 years as well as evaluate their chances for developing late neovascular (wet) AMD based on their risk for late dry (geographic atrophy [GA]) AMD.

Have any companies released their own systems?

Indeed. New York-based, AI-ML-based system developer iHealthScreen, has launched the iPredict, a retinal image-grading system designed to allow non-eye care practitioners (ECPs) to screen for AMD and predict which patients diagnosed with early AMD may be at risk for a later late-stage diagnosis.

The iPredict was trained and validated via a prediction model by iHealthScreen founder Alauddin Bhuiyan, PhD, using 93,830 color fundus images from patients within the early and late AMD groups in the NEI-funded 

[AREDS]). Further validation was provided via images from the Nutritional AMD Treatment-2 

Results from the iPredict included an 86% prediction accuracy in the 2-year risk for progression to late AMD (of the AREDS data) and an 84% prediction accuracy using the NAT-2 data.

A non-ECP can use a fully-automated fundus camera to capture bilateral color images of the retina along with recording pertinent patient data (age, gender, smoking, etc.). The data is sent to a centralized server and is then analyzed by the iPredict’s algorithm for any indications and diagnosis of AMD.

A report is created in approximately 1 minute, which determines whether the patient is referable or non-referable for AMD. For referable patients, a prediction score is generated (0 to 100% scale) that assesses the predictive value of a patient for developing late AMD in the next 1 to 2 years.

That's in progress. The system’s accuracy is currently being tested (

) in a non-ECP setting at four primary care clinics in New York, contracted through the NY Eye and Ear Infirmary.  Providers are screening adults (ages 50+) during annual check-ups; results will be compared to a retinal specialist’s assessments.

Any other AI/ML-based systems being studied?

 one in collaboration with the National Center for Biotechnology Information, an extension of the National Library of Medicine.

While similar in development to the iPredict—in that images from the AREDS study were used—researchers also utilized data of patients with intermediate AMD from the AREDS2 study and trained the model to predict the probability for late AMD progression using AREDS/AREDS2 data.

According to researchers, when validated against an independent test dataset of 601 patients, the model’s prognostic accuracy outperformed that of retinal specialists using two clinical standards.

Both systems are designed to identify reticular pseudodrusen, which is often a challenge to detect due to its composition and location.

Data thus far points to reticular pseudodrusen being connected to a higher risk for late AMD progression inclusive of geographic atrophy; however, scientists state more research is needed to understand its mechanisms.

, the iPredict screening model has been prospectively validated and submitted to the FDA for clearance; if cleared, the company hopes to market it to the primary care practice system by the end of 2023.

Two artificial intelligence/machine learning-based technologies seek to predict patients’ AMD risks in non-eyecare settings.

National Eye Institute

AI-based systems target AMD screening, progression

The American Optometric Association (AOA) 

 that, along with state associations in Florida, Connecticut, and Texas, it will fight new legislation that seeks to potentially block, limit, or discourage doctors of optometry from being referenced as doctors and physicians.

Give me some background on optometry legislation.

According to the AOA, advocacy leaders view state “Not a Doctor” bills as a continuation of the previous American Medical Association-backed campaign previously introduced into legislation (and was ultimately rejected by Congress).

In just the last 2 years, state optometry associations in Wyoming (

) have succeeded in advocating for the passing of bills that expanded the scope of practice for optometrists, including permitting them to perform certain optometric laser procedures in glaucoma and post-cataract care.

, filed in the Florida Senate in February, refers to the usage of health care practitioners’ (HCPs’) titles and abbreviations in advertisements, communications, and personal identification. 

The bill requires for HCPs to disclose the type of license under which an individual practitioner is authorized to provide services along with their title and abbreviations specified by the bill when treating patients.

Further, it lays the groundwork for disciplinary action and license denials by a practitioner's regulatory board.

The AOA stated that, while the bill does not refer to optometry specifically, the title restrictions could set a precedent that might be used against doctors of optometry in regards to their qualifications (and access) to provide patient care, particularly for those specializing in certain areas within the field.

Further, the AOA points out “the proposed ban on the use of the term ‘physician’ in any capacity potentially conflicts with the recognition of physician status for optometrists under federal law utilized by Medicare.”

In Connecticut, optometrists are excluded from 

, which targets concerns regarding health care providers’ advertising.

 was also introduced into the Texas Senate in February and pertains to the regulation of certain health care professionals and facilities (specifically affecting the nursing profession).

While Texas’s bill—in its current form—wouldn’t affect optometrists, the Texas Optometric Association’s director of advocacy, Tommy Lucas, OD, advised that states should be vigilant  “in protecting patients from confusing public policy that would potentially delay and hinder their important eye care.”

: The information provided in this article does not, and is not intended to constitute legal advice; instead, all information, content, materials available herein are for general information purposes only.

Legislation is potentially seeking to limit optometrists’ status as doctors and physicians. 

American Optometric Association

AOA to fight Florida Senate’s ‘Not a doctor’ bill 

 by the American Optometric Association (AOA) is shedding light on today’s myopia management practices among optometrists.

The AOA received responses from 464 optometrists across 41 states and the District of Columbia regarding their myopia management experience and current practices.

Nearly 70% of respondents reported that they presently provide myopia management services; of those, 93% practice in a metropolitan area and 71% work in an independent practice.

Just under three-quarters (73%) said that an annual progression of 0.5 to 0.75 diopters is acceptable before starting protocols for myopia management.

What’s their take on major risk factors?

Respondents ranked refractive error as the most important to consider, followed by (in order):

FDA-approved soft contact lenses were the top-ranking treatment of choice among respondents, followed closely behind by off-label soft multifocal lenses, atropine therapy, and orthokeratology. 

However, they also noted a potential inaccuracy in preference order for treatment methods, as the methods might be combined based on: patients’ ages and disease progression; patient/parent of a patients’ preference; or usage of executive/wide segment bifocals. (

Peripheral defocus spectacles ranked high by a landslide (69%), followed very distantly by progressive addition spectacles (37%), single-vision contact lenses/spectacles (36%), and orthokeratology (30%).

What’s the consensus on atropine doses?

The vast majority (80%) reported using atropine therapy for management. Out of that, a concentration of 0.05% was the most popular dosage (reported by 42%), followed by 0.025% (34%), and—distantly—0.01% (15%).

Sixty-three percent of respondents said they’d prefer more education on myopia control and management; 57% would prefer more education on patient engagement strategies; 50% want insurance coverage for myopia management; and 46% requested diversity in cost of interventions.

Optometrists’ input on current myopia treatments, best practices, and overall education provides an opportunity for the AOA to take action in developing potential resources and strategies for disease management and prevention. (

Optometrists across the nation weighed in on their best practices, treatment, and overall outlook. 

AOA survey finds ODs are embracing myopia management

Bloomberg reports that Novartis AG is working with an adviser to determine potential sales for its front-of-eye treatment assets.

 the company’s plans to sell off all or some of its ophthalmology and respiratory franchises, following the recent consolidation of the oncology and pharmaceuticals units as part of a major overhaul earlier in the year (in which it 

The ophthalmology and respiratory franchises are non-core assets, meaning they’re not included in the five core therapeutic areas and technology platforms the company announced plans to focus on in the future.

How much is the ophthalmology franchise worth?

Per Bloomberg, Xiidra—which Novartis acquired from Takeda Pharmaceutical Co. in 2019—is included in the potential sale. The dry eye drug has generated $487 million in sales revenue for 2022.

Speculating reports are that Novartis has been unable to broaden sales revenues much beyond the $400 million mark it was making prior to the acquisition.

Bloomberg also stated that, according to sources, that Lucentis, indicated for wet age-related macular degeneration (AMD), is not currently included in the for-sale assets. The drug garnered $1.9 billion in sales in 2022.

Despite these reports, per Bloomberg, a Novartis spokesperson stated that deliberations are still ongoing and the company could ultimately decide to retain its assets (including Xiidra).

HEADLINES

Referral rates impact perception of low vision services

Bausch + Lomb, Novaliq release second phase 3 data for NOV03

New data on DR progression in Native Americans

FEATURED

Haag-Streit launches new corneal ectasia display for Eyestar 900

TRENDING

AOA to fight Florida Senate’s ‘Not a doctor’ bill

AOA survey finds ODs are embracing myopia management

Novartis is (reportedly) starting to sell its ophthalmology assets

Nationwide recall issued for two more eye drop products

Business

Novartis is (reportedly) starting to sell its ophthalmology assets

Pediatric vision screening platform GoCheck Kids names new CEO

EyeCheq adds new exec in mission to target early diagnosis of blinding diseases

Viatris appoints new CEO

Research

Referral rates impact perception of low vision services

New data on DR progression in Native Americans

Consuming more calcium may decrease AMD risk

Data suggest PCH eye drops may significantly relieve DED symptoms

Pipeline

Bausch + Lomb, Novaliq release second phase 3 data for NOV03

Visus completes enrollment for phase 3 trial of Brimochol PF for presbyopia

Kuria Therapeutics completes FDA pre-IND consult for CED candidate

Aviceda submits IND for AVD-104 to treat GA secondary to AMD

Products

Haag-Streit launches new corneal ectasia display for Eyestar 900

Death toll rises in artificial tears recall

AI-based systems target AMD screening, progression

NovaBay partners with Eyeganics for OTC organic eye drop

Legal

AOA to fight Florida Senate’s ‘Not a doctor’ bill

What to know about Akorn Pharma's bankruptcy

FTC warns ECPs of legal action for potential Contact Lens Rule violations

FDA warns RightEye of violations with vision system

Archives

Hello 2023 — Weekly Glance

Can we treat uveitis without steroids? — Weekly Glance

Can I have one dilation drop instead of two? — Weekly Glance

Are those dilation reversal drops available yet? — Weekly Glance

Events

FTC to host public workshop on proposed Eyeglass Rule changes

Eyes On Dry Eye raises over $1K for Sjögren’s Foundation

Eyes On Dry Eye exceeds industry expectations

Eyes On Eyecare launches inaugural Eyes On Myopia event